A flurry of press reports in the UK indicates that ProStrakan will delay the sale of shares in its market debut. Morgan Stanley has been working to drum up interest in the flotation despite a terrible market environment that has forced a string of biotechs to scrap plans for going public in recent weeks.
- read this story from Marketwatch for more